Literature DB >> 6864687

D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.

L S Shapiro, R K Prince, R B Buckingham, G P Rodnan.   

Abstract

Punch biopsies of skin were obtained from the forearms of 3 patients with progressive systemic sclerosis with diffuse scleroderma before and after treatment for 1 year or more with D-penicillamine. While on therapy, each patient studied had demonstrated a marked reduction in skin thickening. Collagenase-sensitive protein and glycosaminoglycan accumulation were measured in fibroblast cultures derived from these biopsies. No differences were observed pre- and post-treatment. We conclude that although D-penicillamine may exert its effect in vivo on connective tissue synthesis, maturation and/or turnover, fibroblasts remaining in the thinned dermis retain their potential for increased synthesis of connective tissue.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6864687

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  The current treatment of scleroderma.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

2.  Penicillamine in systemic sclerosis: a reappraisal.

Authors:  M A Sattar; R T Guindi; T N Sugathan
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

Review 3.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.